Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Nephrology

Prognosis & Survivorship: Monitoring Your Long-Term Health

At a Glance

While MPGN and C3G are chronic progressive kidney diseases, proactive monitoring of protein levels (UPCR) and kidney function (eGFR) helps protect long-term health. New targeted therapies and complement inhibitors are also improving the outlook for patients needing kidney transplants.

Managing MPGN (Membranoproliferative Glomerulonephritis) or C3G (C3 Glomerulopathy) is a marathon, not a sprint. Because these conditions are chronic and progressive, the focus of your care will shift over time from diagnosis to long-term monitoring and protection of your kidney function. While the outlook for these diseases can be challenging, a proactive approach to monitoring and the arrival of new treatments provide a clear path forward [1][2].

Understanding the Risk of Progression

Both IC-MPGN and C3G are associated with a risk of progressing to ESRD (End-Stage Renal Disease), which is the stage where the kidneys can no longer function on their own [1][3]. Several key markers help your doctor estimate how your disease might behave over time [4][5]:

  • Proteinuria Levels: Losing more than 3.5 grams of protein per day in your urine is a major risk factor for faster progression [4][6].
  • eGFR (Glomerular Filtration Rate): This is the measure of how well your kidneys are filtering. A low starting eGFR or a rapid drop in this number over time indicates higher risk [5][7].
  • Biopsy Clues: On your biopsy report, a high chronicity score (which measures permanent scarring) or the presence of crescents (a sign of rapid inflammation) can suggest a more aggressive course [4][8][9].

Long-Term Monitoring: Your Lab Routine

To stay ahead of the disease, you and your doctor will track specific lab values, typically every 1 to 3 months depending on your stability [10]. These markers act as a “dashboard” for your kidney health:

  1. UPCR (Urine Protein/Creatinine Ratio): This is the primary tool for measuring proteinuria. Lowering this number is the most important way to improve your long-term prognosis [6][11].
  2. eGFR Trend: Rather than focusing on a single reading, your doctor will look at the trend of your eGFR over several months to see if your kidney function is stable [12][5].
  3. Complement Levels (C3 and C4): Monitoring the proteins in your immune system can help your doctor see if your treatment is effectively “turning off” the overactive complement pathway [13][14].

Thinking Ahead: Kidney Transplantation

For patients whose disease progresses to kidney failure, transplantation is a common goal. It is important to know that MPGN and C3G have a risk of recurrence, meaning the disease can return in the new kidney [15][16].

While the recurrence rate is approximately 25%, the landscape of transplantation is changing [15]. In the past, there were few ways to treat recurrent disease, but new complement inhibitors (like Iptacopan and Pegcetacoplan) are now being used to manage the disease after transplant [17][18][19]. If you are a candidate for a transplant, your team will perform specialized testing—including genetic screens—to help manage this risk [20][21].

Hope and Survivorship

The “standard” prognosis for MPGN is based on data from years ago, before the arrival of targeted therapies. Today, with the ability to target the root cause of complement activation and better tools for monitoring protein loss, many patients are living longer with stable kidney function [17][22]. Staying engaged with your care team and monitoring your lab trends are the best ways to protect your health for the years to come [6][23].

Return to Home

Common questions in this guide

What signs show that my MPGN or C3G is progressing?
Your doctor will monitor your urine protein levels, your estimated glomerular filtration rate (eGFR), and specific findings on your kidney biopsy. Losing more than 3.5 grams of protein a day or having a rapid drop in eGFR indicate a higher risk of disease progression.
How often will I need lab tests for C3G or MPGN?
Most patients have their labs checked every 1 to 3 months, depending on how stable their disease is. These routine tests usually check your protein levels (UPCR), kidney filtering function (eGFR), and complement protein levels (C3 and C4).
Can I get a kidney transplant if I have MPGN?
Yes, a kidney transplant is a standard goal for patients who reach end-stage renal disease. While there is an approximate 25% risk that the disease can return in the new kidney, new medications called complement inhibitors are now available to help manage this risk.
What does the chronicity score on my kidney biopsy mean?
A chronicity score measures the amount of permanent scarring present in your kidney tissue. A higher score suggests that the disease has caused lasting damage and may progress more rapidly, which helps your nephrologist plan your care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my 'chronicity score' and 'activity index' on my biopsy, and what do they mean for my long-term outlook?
  2. 2.How often should I be getting my UPCR and eGFR checked to ensure we catch any changes early?
  3. 3.If I eventually need a kidney transplant, what steps will we take to monitor for recurrence in the new kidney?
  4. 4.Are my current protein levels considered 'high risk' for progression, and what can we do to bring them down further?
  5. 5.Do I have any specific genetic markers or autoantibodies (like C3 nephritic factors) that make my case more aggressive?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Clinical features and outcomes of immune complex-membranoproliferative glomerulonephritis and C3 glomerulopathy: a multicenter observational cohort study analyzing kidney biopsy cases.

    Kim S, Choi YE, Kim SG, et al.

    Kidney research and clinical practice 2024; doi:10.23876/j.krcp.24.129.

    PMID: 39980095
  2. 2

    Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative GN.

    Caravaca-Fontan F, Norouzi S, Huang M, et al.

    Kidney360 2026; (7(3)):547-559 doi:10.34067/KID.0000001059.

    PMID: 41359393
  3. 3

    Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis.

    Khandelwal P, Bhardwaj S, Singh G, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(3)):591-600 doi:10.1007/s00467-020-04736-8.

    PMID: 32886193
  4. 4

    Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN.

    Nanchen G, Marasà M, Breno M, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2026; (21(4)):626-640 doi:10.2215/CJN.0000000953.

    PMID: 41433110
  5. 5

    Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.

    Nakagawa N, Mizuno M, Kato S, et al.

    PloS one 2021; (16(9)):e0257397 doi:10.1371/journal.pone.0257397.

    PMID: 34520493
  6. 6

    Delphi Consensus on Surrogate End Points in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

    Caravaca-Fontán F, Fakhouri F, Licht C, et al.

    Kidney international reports 2026; (11(2)):103671 doi:10.1016/j.ekir.2025.10.028.

    PMID: 41502799
  7. 7

    Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015.

    Nakagawa N, Hasebe N, Hattori M, et al.

    Clinical and experimental nephrology 2018; (22(4)):797-807 doi:10.1007/s10157-017-1513-7.

    PMID: 29214407
  8. 8

    Clinical characteristics and short term outcomes of childhood immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy: a single centre retrospective study.

    Bajeer IA, Khatri S, Kumar P, et al.

    BMC nephrology 2025; (26(1)):143 doi:10.1186/s12882-025-04078-3.

    PMID: 40121417
  9. 9

    Crescentic glomerulonephritis associated with myelodysplatic syndrome and visceral leishmaniasis.

    Decaestecker A, Daniel A, Malbranque Z, et al.

    Journal of nephrology 2025; (38(7)):1999-2004 doi:10.1007/s40620-025-02329-y.

    PMID: 40537698
  10. 10

    Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis.

    Kawasaki Y, Kanno S, Ono A, et al.

    Pediatric nephrology (Berlin, Germany) 2016; (31(7)):1091-9 doi:10.1007/s00467-015-3307-z.

    PMID: 26846787
  11. 11

    Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN.

    Ghaddar M, Caravaca-Fontán F, Praga M, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2025; (20(8)):1119-1131 doi:10.2215/CJN.0000000751.

    PMID: 40512548
  12. 12

    Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis.

    Kavanagh D, Ariceta G, Vivarelli M, et al.

    Kidney international reports 2026; (11(1)):17-31 doi:10.1016/j.ekir.2025.10.020.

    PMID: 41541782
  13. 13

    Functional Characterization of Anti-C3bBb Autoantibodies and C3 Glomerulopathy Phenotype.

    Roquigny J, Meuleman MS, El Sissy C, et al.

    Journal of the American Society of Nephrology : JASN 2025; (36(2)):264-273 doi:10.1681/ASN.0000000000000499.

    PMID: 39325562
  14. 14

    Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy.

    Meuleman MS, Petitprez F, Pickering MC, et al.

    Journal of the American Society of Nephrology : JASN 2024; (35(8)):1034-1044 doi:10.1681/ASN.0000000000000373.

    PMID: 38709564
  15. 15

    Recurrent Membranoproliferative Glomerulonephritis After Kidney Transplantation: Risk Factors and Impact on Graft Survival.

    de Paula LC, Mazzali M, de Sousa MV

    Annals of transplantation 2023; (28()):e940502 doi:10.12659/AOT.940502.

    PMID: 37461201
  16. 16

    Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation.

    Caravaca-Fontán F, Polanco N, Villacorta B, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(1)):222-235 doi:10.1093/ndt/gfac148.

    PMID: 35404425
  17. 17

    Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

    Fakhouri F, Bomback AS, Ariceta G, et al.

    The New England journal of medicine 2025; (393(22)):2210-2220 doi:10.1056/NEJMoa2501510.

    PMID: 41337715
  18. 18

    Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment.

    Filippone EJ, Farber JL

    Frontiers in nephrology 2026; (6()):1747678 doi:10.3389/fneph.2026.1747678.

    PMID: 41767602
  19. 19

    Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases.

    Escudero-Saiz VJ, Gonzalez Á, García-Herrera A, et al.

    Kidney medicine 2024; (6(6)):100823 doi:10.1016/j.xkme.2024.100823.

    PMID: 38741947
  20. 20

    Genetic diagnosis of kidney disease by whole exome sequencing and its clinical application.

    Jung J, Lee JH, Seo GH, et al.

    Clinical genetics 2023; (104(3)):298-312 doi:10.1111/cge.14382.

    PMID: 37270787
  21. 21

    Diagnostic Yield of Next-Generation Sequencing in Patients With Chronic Kidney Disease of Unknown Etiology.

    de Haan A, Eijgelsheim M, Vogt L, et al.

    Frontiers in genetics 2019; (10()):1264 doi:10.3389/fgene.2019.01264.

    PMID: 31921302
  22. 22

    Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.

    Bomback AS, Daina E, Remuzzi G, et al.

    Kidney international reports 2025; (10(1)):87-98 doi:10.1016/j.ekir.2024.09.030.

    PMID: 39810766
  23. 23

    Recurrence of C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis After Kidney Transplantation: Challenges and Opportunities.

    Ruiz-Cabello JE, Trujillo H, Cavero T, et al.

    Kidney international reports 2026; (11(2)):103682 doi:10.1016/j.ekir.2025.11.008.

    PMID: 41502804

This page provides educational information on the long-term prognosis for MPGN and C3G. It does not replace professional medical advice. Always discuss your specific prognosis, lab trends, and transplant options with your nephrologist.

Get notified when new evidence is published on Primary membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.